Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 390 participants.

Also called NCT02829151

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 390 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02829151
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02829151. Randomized; no masking; primary purpose treatment. Start 2017-02-21 (actual); primary completion 2021-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)
Condition
Critical Limb Ischemia
Intervention (Drug)
Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )
Intervention (Drug)
Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel
Intervention (Drug)
Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol
Lead sponsor
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct02829151
Content hash
f1f51786463d84947e135ae450e07498d5f1996edad69be22e36fdd864b1cefb